Lupin Ltd
5 products tracked · names used in filings: Lupin Ltd, Lupin Limited, Lupin Europe GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Wed 15 Jul 2026🇪🇺 EU approval (EC decision)
Vislyfa (ranibizumab) approved in the EU
Marketing authorisation to Lupin Europe GmbH; Biosimilar, Additional monitoring · source
Tue 02 Jun 2026🇺🇸 FDA approval
FDA approves biosimilar Ranluspec (ranibizumab-hkdz)
Lupin Limited; BLA761480; Biosimilar; injection · source
Thu 21 May 2026🇪🇺 CHMP positive opinion
Vislyfa (ranibizumab): CHMP positive opinion
Lupin Europe GmbH; Biosimilar, Additional monitoring · source
Tue 10 Feb 2026🇪🇺 EU approval (EC decision)
Ranluspec (ranibizumab) approved in the EU
Marketing authorisation to Lupin Europe GmbH; Biosimilar, Additional monitoring · source
Thu 11 Dec 2025🇪🇺 CHMP positive opinion
Ranluspec (ranibizumab): CHMP positive opinion
Lupin Europe GmbH; Biosimilar, Additional monitoring · source
Fri 28 Nov 2025🇺🇸 FDA approval
FDA approves biosimilar Armlupeg (pegfilgrastim-unne)
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Vislyfa ranibizumab | Authorised | 2026-07-15 |
| 🇺🇸 | Ranluspec ranibizumab-hkdz | Approved | 2026-06-02 |
| 🇪🇺 | Ranluspec ranibizumab | Authorised | 2026-02-10 |
| 🇺🇸 | Armlupeg pegfilgrastim-unne | Approved | 2025-11-28 |
| 🇪🇺 | Namuscla Mexiletine | Authorised | 2018-12-18 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.